Sarcoma News
Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading
Cancer Deaths on the Decline (February 11, 2013)Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading
Shorter Chemotherapy Intervals Effective in Ewing Sarcoma (November 1, 2012)In patients with localized Ewing sarcoma, chemotherapy administered every two weeks is more effective than chemotherapy administered every three weeks, with no increase in toxicity, according to the results of a study published in the Journal of Clinical... Continue Reading
Regorafenib May Expand GIST Treatment Options (June 13, 2012)Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III clinical trial—were presented at the 2012 Annual... Continue Reading
Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading
Votrient Approved for the Treatment of Sarcoma (May 7, 2012)The U.S. Food and Drug Administration (FDA) has approved Votrient® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. It is the first new drug in decades to treat this type of cancer. Soft... Continue Reading
Longer Treatment with Gleevec Effective Against Gastrointestinal Stromal Tumors (GIST) (April 9, 2012)In a Phase III clinical trial, three years of adjuvant (post-surgery) treatment with Gleevec® (imatinib) resulted in better survival than one year of adjuvant treatment among patients with high-risk gastrointestinal stromal tumors (GIST). These results... Continue Reading
Genetic Change Linked with Rhabdomyosarcoma Survival (April 4, 2012)For children with rhabdomyosarcoma, a test for a specific genetic change could eventually improve risk estimates and treatment decisions. These results were published in the Journal of Clinical Oncology. Rhabdomyosarcoma is a soft-tissue cancer that arises... Continue Reading
Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading
FDA Updates Use of Gleevec for Gastrointestinal Stromal Tumors (February 29, 2012)In changes approved by the US Food and Drug Administration (FDA), the prescribing information for Gleevec® (imatinib) now notes that three years of adjuvant (post-surgery) treatment results in better survival than one year of adjuvant treatment among... Continue Reading
Latest Sarcoma News By Stage
Ewing's Sarcoma Overview
Shorter Chemotherapy Intervals Effective in Ewing Sarcoma (November 1, 2012)
In patients with localized Ewing sarcoma, chemotherapy administered every two weeks is more effective than chemotherapy administered every three weeks, with no increase in toxicity, according to the results of a study published in the Journal of Clinical... Continue Reading
Children with Ewing’s Sarcoma or Astrocytoma Most Likely to Experience Late Recurrence (February 19, 2010)Late recurrence of childhood cancers appears to occur most often in Ewing’s sarcoma and astrocytoma, according to the results of a study published in the Journal of the National Cancer Institute. As cancer treatment has improved and evolved, the number... Continue Reading
Children with Ewing’s Sarcoma or Astrocytoma Most Likely to Experience Late Recurrence (February 19, 2010)Late recurrence of childhood cancers appears to occur most often in Ewing’s sarcoma and astrocytoma, according to the results of a study published in the Journal of the National Cancer Institute. As cancer treatment has improved and evolved, the number... Continue Reading
More Ewing's Sarcoma OverviewGeneral Sarcoma
Regorafenib May Expand GIST Treatment Options (June 13, 2012)
Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III clinical trial—were presented at the 2012 Annual... Continue Reading
Votrient Approved for the Treatment of Sarcoma (May 7, 2012)The U.S. Food and Drug Administration (FDA) has approved Votrient® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. It is the first new drug in decades to treat this type of cancer. Soft... Continue Reading
Longer Treatment with Gleevec Effective Against Gastrointestinal Stromal Tumors (GIST) (April 9, 2012)In a Phase III clinical trial, three years of adjuvant (post-surgery) treatment with Gleevec® (imatinib) resulted in better survival than one year of adjuvant treatment among patients with high-risk gastrointestinal stromal tumors (GIST). These results... Continue Reading
Genetic Change Linked with Rhabdomyosarcoma Survival (April 4, 2012)For children with rhabdomyosarcoma, a test for a specific genetic change could eventually improve risk estimates and treatment decisions. These results were published in the Journal of Clinical Oncology. Rhabdomyosarcoma is a soft-tissue cancer that arises... Continue Reading
FDA Updates Use of Gleevec for Gastrointestinal Stromal Tumors (February 29, 2012)In changes approved by the US Food and Drug Administration (FDA), the prescribing information for Gleevec® (imatinib) now notes that three years of adjuvant (post-surgery) treatment results in better survival than one year of adjuvant treatment among... Continue Reading
More General SarcomaSoft Tissue Sarcomas
Regorafenib May Expand GIST Treatment Options (June 13, 2012)
Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III clinical trial—were presented at the 2012 Annual... Continue Reading
More Soft Tissue Sarcomas